

(12) **UK Patent Application** (19) **GB** (11) **2 201 685** (13) **A**  
(43) Application published 7 Sep 1988

(21) Application No 8704904

(22) Date of filing 3 Mar 1987

(71) Applicants  
2 Moskovsky Gosudarstvenny Meditsinsky Institut  
Imeni N.I. Pirogova

(Incorporated in USSR)

Moscow, ulitsa Ostrovitvanova 1,  
Union of Soviet Socialist Republics

Vsesojuzny Nauchno-Issledovatel'sky I Ispytatelny  
Institut Meditsinskoi Tekhniki

(Incorporated in USSR)

Moscow, ulitsa Kasatkina 3,  
Union of Soviet Socialist Republics

(72) Inventors  
Alla Yakovlevna Akimova  
Valentin Mikhailovich Buyanov  
Eduard Izraelovich Galperin  
Anatoly Borisovich Davydov  
Valery Nikolaevich Eglev  
Svetlana Mikhailovna Kremli

(51) INT CL<sup>4</sup>  
C09J 3/00 A61K 49/04 C08K 5/00// (C08K 5/00 5:07  
5:09 5:41)

(52) Domestic classification (Edition J):  
C3V BD BF  
C3W 227 302  
U1S 1025 1369 3001 C3V

(56) Documents cited  
None

(58) Field of search  
C3V  
C3K  
C3P

Nikolai Fedorovich Kuzovlev  
Natalya Anatolievna Lukyanova  
Valeria Iosifovna Timokhina

(74) Agent and/or Address for Service  
Marks & Clerk  
57-60 Lincoln's Inn Fields, London, WC2A 3LS

(54) Composition for occlusion of ducts and cavities of human body

(57) The present invention relates to compositions for occlusion of ducts and cavities of the human body.

The composition incorporates an alpha-cyanoacrylate, dimethylsulphoxide, dimethylketone and an iodine-containing radiopaque organic acid, or mixtures of such acids, the weight percentages of the constituents being as follows:

alpha-cyanoacrylate	25 to 42
dimethylsulphoxide	12 to 25
dimethylketone	20 to 24
iodine-containing radiopaque organic acid, or mixtures of such acids	9 to 43

The composition may also include 5 - 11 % by weight of polyvinyl acetate.

GB 2 201 685 A

COMPOSITION FOR OCCLUSION OF DUCTS AND  
CAVITIES OF HUMAN BODY

The present invention relates generally to medicine and more specifically to compositions applied for occlusion of ducts and cavities in human organism, e.g., for plugging or filling pancreatic ducts, blood vessels, the bronchi, cyste, abscesses or dental canals.

According to the invention there is proposed such a composition for occlusion of ducts and cavities of human body that comprises alpha-cyanoacrylates and wherein, according to the invention, there are also contained dimethylsulphoxide, dimethylketone and an iodine-containing radiopaque organic acid, or mixtures of such acids, the weight percentage ratio of the original constituents being as follows:

alpha-cyanoacrylate	25 to 42
dimethylsulphoxide	12 to 25
dimethylketone	20 to 24
iodine-containing radiopaque organic acid or mixtures of such acids	9 to 43

To prolong the period within which the plug retains its solidity, the composition for occlusion of ducts and cavities of human body may additionally be doped with polyvinylacetate having a molecular mass of 15000 to 25000, in an amount of 5 to 11 weight percent of the total amount of alpha-cyanoacrylate.

Use of the components enlisted above in the afore-

mentioned ratio provides for a whole set of the physico-chemical and medicobiological characteristics required for the present composition.

5 The proposed composition may comprise as alpha-cyanoacrylates such ones as, e.g., ethyl-alpha-cyanoacrylate, ethoxyethyl-alpha-cyanoacrylate, or a mixture thereof.

10 The composition for occlusion of ducts and cavities of human body may comprise as the iodine-containing radiopaque organic acids such ones as alpha-phenyl-beta-(3,5-diiodo-4-hydroxyphenyl) propionic acid, 3-acetylaminomethyl-5-acetyl-amino-2,4,6-tri-iodobenzoic acid, or alpha-(3-amino-2,4,6-tri-iodobenzyl) butyric acid.

15 With the percentage content of alpha-cyanoacrylate less than 25 the composition does not possess adhesive properties, while its biological destruction occurs within 15 and 25 days. When the alpha-cyanoacrylate percentage content exceeds 42 the composition solidifies very quickly on getting in contact with body tissues the setting time being under one minute).

20 The weight percentage content of dimethylsulphoxide below 12 results in a longer setting time (up to 4 or 6 minutes) of the composition on its getting contact with body tissues, which might eventuate in a back flow of the composition. With the dimethylsulphoxide percentage content above 25 the period of polymerization of the composition in the air is badly reduced (below ten minutes), which complicates much the handling of

the composition. With the weight percentage content of iodine-containing radiopaque organic acids below 9 radiopacity of the resultant plug is not provided. The weight percentage content of said acids exceeding 44  
5 results in a slower rate of solidification of the composition on getting in contact with human tissues and in a rather quick loss of solidity by the resultant plug. Application of dimethylketone in the aforespecified quantity in combination with other components  
10 of the composition provides for the necessary polymerization time of the composition in the air on getting in contact with body tissues.

The herein-proposed composition for occlusion of ducts and cavities of human body has been tested experimentally on animals and in humans clinically. The composition has been tested for efficacy in occlusion of the pancreatic ducts on intact pancreatic glands of sexually mature mongrel dogs weighing from 6 to 35 kg. The procedure is as follows. The supramedian laparotomy  
15 is carried out under intravenous hexenal anesthesia; the minor (accessory) pancreatic duct is ligated; a polyvinylchloride catheter is introduced extraduodenally into the major pancreatic duct for a depth of 0.3 to 0.5 cm and fixed by ligation therein. The proposed composition is  
20 injected within 30 to 50 seconds along the catheter in an amount of 0.6 to 2 ml, whereupon the catheter is withdrawn and the duct is ligated. As the control the occlusion of the pancreatic ducts has been performed

according to the same procedure, using a silicone elastomer and ethyl-alpha-cyanoacrylate. The surgical procedure is followed by determining the changes in the level of amylase, trypsin, immunoreactive insulin, C-peptide, glucose, Some macroscopic and histologic examinations are carried out in different postoperative terms to study into the rate of atrophy of the pancreas, the decomposition rate of the thus-formed polymer, the rate of positive results.

The rate of positive results of studies performed is expressed by the following relationship and is determined from the formula  $n = \frac{A}{T} \cdot 100\%$ , where n means the rate of positive results, A is the number of animals that have developed complete atrophy of the pancreas, T, stands for a total amount of test animals. The rate of atrophy is determined by the formula:  $V = \frac{1}{t}$ , where V is the rate of atrophy and t is the lapse of time, within which complete atrophy of the exocrine portion of the pancreas takes place, characterized by the absence of acinar cells upon histologic examination.

The rate of the polymer decomposition is in fact the lapse of time within which the preformed polymer plug is completely destructed and brought out of the organism. The rate of decomposition is determined macroscopically against the absence of polymer in the major pancreatic duct upon postmortem examination of the test animals.

The results obtained are tabulated in Tables 1 and 2

Table 1

Effect of the proposed composition on  
variations in the amylase level

Chemical substance applied	Number of test dogs	Maximum ele- vation of the level (percent of the initial amylase level)	Duration of hy- pera- myla- semis (days)
Proposed compo- sition	25	550	10 $\pm$ 2
Silicone elasto- mer	15	2120 <sup>x</sup>	15 $\pm$ 3 <sup>x</sup>
Ethyl-alpha-cyano- acrylate	10	715	14 $\pm$ 2
<sup>x</sup> Statistically valid difference p 0.05			

Table 2

Effect of the proposed composition on the  
rate of pancreas atrophy and percentage of  
positive results

Chemical sub- stance appli- ed	Number of test dogs	Rate of pancreas atrophy (days)	Percentage of positive results
1	2	3	4
Proposed com- position	25	45 $\pm$ 7	100
Silicone elas-			

Table 2

1	2	3	4
tomer	15	76 $\pm$ 14 <sup>x</sup>	70 <sup>x</sup>
Ethyl-alpha-cyano- acrylate	10	65 $\pm$ 11 <sup>x</sup>	60 <sup>x</sup>
<sup>x</sup> Statistically valid difference p 0.05			

No statistically reliable difference between the aforesated compositions has been found upon studying the changes in the level of trypsin, immunoreactive insulin, C-peptide, glucose.

5 When investigating in to the polymer decomposition rate, the polymer has been found to completely fill the major pancreatic duct as well as the ducts of the 1st and 2nd order in 15 days after surgery 1 to 1.5 months after surgery the polymer has been observed to lodge  
10 in the major pancreatic duct as individual conglomerates. No polymer is detected in the major pancreatic duct on postmortem examination 2 or 3 months after surgery.

In a separate run of experiments the proposed composition has been tested for applicability in endoscopic  
15 occlusion. With this purpose in view, laparotomy is immediately followed by duodenotomy. The major pancreatic duct is catheterized transduodenally, whereupon the proposed composition for occlusion of ducts and cavities of human body is injected without ligsting the  
20 accessory pancreatic duct in an amount equal to the volumetric capacity of the entire system of the pancrea-

tic ducts. As the control a similar surgical procedure has been performed using silicone elastomer as the occluding composition. The complete pancreas atrophy has occurred in 6 test dogs out of 7 that have been given  
5 the proposed composition for occlusion of the pancreatic ducts (the percentage of the positive results being 86), whereas the complete pancreas atrophy has been found to occur only in two out of six test dogs, wherein occlusion has been made with silicone elastomer (the  
10 percentage of positive results being 33).

Thus, experimental application of the proposed composition for occlusion of the pancreatic ducts brings about 100-percent atrophy of the exocrinous portion of the pancreas, the function of the Langerhans' islets  
15 remaining unaffected, which is much more statistically valid as compared with other compositions. The rate of atrophy of the pancreas exocrinous portion is enhanced, i.e. the time required for the complete atrophy of the acinar tissue is reduced, the fact that is of paramount  
20 importance from the viewpoint of clinical application of the proposed composition. In addition, manifestations of acute edematous pancreatitis subside significantly after occlusion of the pancreatic ducts with the use of the proposed composition, which is evidenced  
25 by a lower elevation of amylase and shorter duration of hyperamylasemia. The proposed composition for occlusion of ducts and cavities of human body is much more efficacious, as compared with silicone elasto-



mer, in experimental endoscopic occlusion of the pancreatic ducts, which manifests itself in higher percentage of the postocclusion positive results.

5 The proposed composition has been tested for efficacy in experimental embolization of blood vessels. Experiments have been conducted on ten male rabbits weighing 3 to 3.5 kg each, under general ether anesthesia. The composition taken in an amount of 5 to 10 ml is injected into the femoral artery through a 30 to 10 50 cm long, 1 mm diameter catheter. The experiments carried out demonstrate that the composition can readily be injected into blood vessels through the catheter of the aforementioned calibre and length, whereby a possibility is provided for the composition to administer 15 into various blood vessels of both medium and small calibre. Test animals tolerate well the surgical procedure for injection of the composition into the femoral artery, no symptoms of a general toxic effect being observed. A clear-cut embolizing effect is attained in 100 per- 20 cent of the cases.

The proposed composition for occlusion of ducts and cavities of human body has been tested in 17 patients who have been treated in three clinical hospitals. According to the diagnoses the patients fall into the 25 following groups:

Posttraumatic external pancreatic	
fistula	4
Chronic pancreatitis	7

Tumor of the pancreatic

head 4

Total hemorrhagic pancreatomecro-

sis 2

5 Age span of the patients is 28  
and 73 years.

The patients were subjected to a general clinical  
examination, endoscopic retrograde pancreatocholan-  
giography, sonography of the liver, biliary, tract,  
10 pancreas both within the pre- and postoperative periods.  
Roentgenography of the abdominal viscera was also car-  
ried out.

One patient (out of the four patients in whome  
occlusion of the fistular cavity and of part of the  
15 pancreatic duct was carried out) developed recanali-  
zation of the duct system within the postoperative pe-  
riod that required repeated occlusion. No other postope-  
rative complications were observed. No reliable evi-  
dence about any changes in the state of the patients  
20 after occlusion of the fistular cavity was obtained  
by the general clinical examination procedure. Sono-  
graphic examinations revealed induration and gradual  
reduction of the pancreas portion involved in the fis-  
tula. Observation X-ray radiography demonstrated that  
25 radiopacity of the composition for occlusion of ducts  
and cavities of human body retained within 10 to 15 days  
after surgery, which made it possible to carry out  
occlusion of the fistular cavity and of the pancreatic

ducts under radiological monitoring, as well as to perform postoperative control of the location of the composition for occlusion of ducts and cavities of human body. An average period of postoperative in-hospital stay of the patients was 5 to 7 days.

Glucose tolerance tests carried out in six and twelve months after surgery demonstrated normal functioning of the Langerhans' islets.

In seven patients there was carried out occlusion with the aid of the proposed composition for a severe form of chronic painful pancreatitis, of whom five patients were given the procedure within the intraoperative period, and two patients, through the endoscope. The surgery involved laparotomy, duodenotomy, papillosphincterotomy, catheterization of the major pancreatic duct, and total occlusion of the pancreatic duct system with the aid of the proposed composition for occlusion of ducts and cavities of human body, whereupon a purse-string suture was applied to the opening of the major pancreatic duct and tied up after withdrawal of the catheter. Endoscopic occlusion was carried out after pancreatographic examination in order to confirm correct positioning of the catheter. In all the patients operated upon there was observed moderate hyperamylasemia within the postoperative period, on the average for a period up to four days after surgery. No other postoperative complications were observed. All the patients got rid of pain. Observation X-ray

radiography of the abdominal viscera revealed that radiopacity of the proposed composition retained as long as the ten or fifteen days after surgery. No cyst formation was detected upon sonography. All the patients operated upon were subsequently subjected to the control investigation of the function of the Langerhans' islets (that is, to the glucose tolerance test), which showed the absence of the diabetes mellitus. The patients in whose endoscopic occlusion was made have been under observation for more than a year, no relapses being noted.

In four patients there was performed occlusion of the pancreatic stump after the pancreatoduodenal resection made for a tumor of the pancreatic head. No complications were observed on the part of the pancreatic stump within the postoperative period, nor dribbling of the pancreatic juice through the drains out of the abdominal cavity. In two patients there was observed during surgery microfocal fat pancreatonecrosis, which was arrested after occlusion of the pancreatic ducts of the pancreatic stump with the aid of the proposed composition for occlusion of ducts and cavities of human body.

In two patients there was performed occlusion of the pancreatic ducts for total hemorrhagic pancreatonecrosis. There were carried out laparotomy, cholecystectomy, transduodenal papillosphincterotomy, and occlusion of the pancreatic ducts.

The general clinical examinations carried out within the postoperative period, and examinations of amylase and trypsin, gave evidence of rapid (within one or two weeks) subsiding of the inflammatory process.

Intoxication phenomena were observed within two or three days.

No complications on the part of the pancreas were noted within the postoperative period, nor there were detected suppuration of the pancreas necrotic foci and flowing of the pancreatic juice through the drains out of the abdominal cavity. The control glucose tolerance tests carried out in six and twelve months after surgery revealed a mild form of the diabetes mellitus in one patient.

Subacute toxicologic experiment revealed no negative effect of the extracts of the proposed composition for occlusion of ducts and cavities of human body on the biological test-subjects (that is, isolated erythrocytes, isolated frog's heart, isolated bull's sexual cells). The studied functions of the test animals' organism exhibited no substantial difference from those of the control animals (that is, the functions of CNS, liver, kidneys, etc.).

Thus, the proposed composition meets all requirements imposed upon compositions for occlusion of ducts and cavities of human body. The proposed composition is biocompatible, features low initial vis-

cosity, retains fluidity in the air for 10 to 15 minutes, is polymerizable in the ducts and cavities within 1 to 3 minutes, possesses good adhesion to the walls of ducts and cavities, is destructable and is brought out of the organism for one to three months, and features good radiopacity and antiseptic properties.

Clinical trials of the proposed composition for occlusion of ducts and cavities of human body, carried out by the applicants, have proven that the composition is convenient in handling and application. Injection of the composition can be monitored against an X-ray screen. Radiopacity of the proposed composition retains within 10 to 15 days after surgery, which makes it possible to keep watch on the location of the composition in the duct system. No postoperative complications are observed. Glucose tolerance tests carried out in every follow-up term (within one year after surgery) give evidence of a normal functioning of the insular apparatus. There are observed, within long-term follow-ups (up to one year), no cases of incomplete occlusion of the pancreatic ducts, recanalization of the duct system, or cyst formation. It is due to low viscosity and optimum polymerization periods of the proposed composition upon getting in contact with body tissues that the composition is readily injectable through an endoscope and gets polymerized immediately after injection. Application of the composi-

( tion for occlusion of the pancreatic ducts in total hemorrhagic pancreatonecrosis results in subsidence of the inflammatory process, atrophy of the exocrinous portion of the pancreas without formation of abscesses or cysts.

The process for producing the composition for occlusion of ducts and cavities of human body is simple in technological implementation and is carried into effect as follows.

10 The process flowsheet for production of the proposed composition is as follows:

Alpha-cyanoacrylates are taken either individually or in a mixture, next added thereto is dimethylketone in an amount of 5 to 10 weight percent. Thus, the first component of the composition is obtained. Then there is taken an iodine-containing radiopaque organic acid, or a mixture of such acids, and added thereto are dimethylsulphoxide and the rest of dimethylketone, taken in the aforestated ratio. Thus, the second component of the composition is obtained. Both of the aforesaid components may be stored for a prolonged period of time (over one year) in a hermetically sealed package at a temperature of  $0 \pm 5^{\circ}\text{C}$ .

25 To produce the composition for occlusion of ducts and cavities of human body, both of the constituents are to be intermixed immediately before use.

To promote understanding of the invention the

following specific exemplary embodiments are given hereinbelow.

Example 1

The composition produced features the following  
5 weight percentage ratio of the constituents thereof:

	ethyl-alpha-cyanoacrylate	12.5
	ethoxyethyl-alpha-cyano-	
	acrylate	12.5
	dimethylsulphoxide	15
10	dimethylketone	22
	alpha-phenyl-beta-(3,5-diiodo-	
	-4-hydroxyphenyl) propionic	
	acid	38

Added to a mixture of 0.125 g ethyl-alpha-cyano-  
15 noacrylate and 0.125 g ethoxyethyl-alpha-cyanoacrylate  
is dimethylketone in an amount 0.1 g to obtain the  
first component of the composition. Then added to  
0.38 g alpha-phenyl-beta-(3,5-diiodo-4-hydroxyphenyl)  
propionic acid are 0.15 g dimethylsulphoxide and  
20 0.12 g dimethylketone, the ingredients are thoroughly  
mixed to obtain the second component of the composi-  
tion. The thus-obtained components may be kept stored  
in a hermetically sealed container at  $0 \pm 5^{\circ}\text{C}$  for a  
prolonged period of time (over one year). Both of  
25 the components are to be intermixed carefully immedi-  
ately before use.

The polymerization time of the thus-obtained com-  
position in the air at  $25^{\circ}\text{C}$  is 12 minutes. The poly-



rization rate of the composition on getting in contact with body tissues is 1.5 minutes. The composition has been tested experimentally on a mongrel dog weighing 8 kg. The supramedian laparotomy was carried out  
5 under general hexenal anesthesia. The accessory pancreatic duct was ligated. The major pancreatic duct was catheterized extraduodenally with the aid of a dia. 1 mm catheter, which was fixed in place with a ligature.

The aforesaid composition was injected through the  
10 catheter for 45 seconds, whereupon the catheter was withdrawn, and the duct was ligated. The dog was out on a standard diet within the postoperative period. No complications on the part of the pancreas were observed. On postmortem examination in 45 days after surgery  
15 there was noted atrophy of the pancreas, and absence of the plug in the major pancreatic duct. On histologic examination there was detected complete atrophy of the acinar tissue, whereas the Langerhans' islets remained unaffected.

20      Example 2

The composition obtained features the following weight percentage ratio of the constituents thereof:

	ethyl-alpha-cyanoacrylate	21
	ethoxyethyl-alpha-cyanoacry-	
25	late	21
	dimethylsulphoxide	12
	dimethylketone	24
	3-acetylaminomethyl-5-acetyl-	

amino-2,4,6-tri-iodobenzoic

acid

22

The composition is produced according to the process described in Example 1. The polymerization time  
5 of the composition in the air at 25°C is 11 minutes. The rate of polymerization of the composition on getting in contact with body tissues is 1 minute.

The composition has been trialled clinically in male patient G aged 60, operated upon for total hemorrhagic pancreatonecrosis. The patient was subjected  
10 to choledochotomy, papillosphincterotomy, and retrograde occlusion of the pancreatic ducts with the aid of the proposed composition for occlusion of ducts and cavities of human body, taken in an amount of 7 ml. An  
15 intensive infusion therapy was carried out within the postoperative period. No complications on the part of the pancreas were observed within the postoperative period. Radiopacity of the composition, which was  
checked with the aid of observation X-ray radiography  
20 of the abdominal viscera, was found to remain up to the 15th day after surgery, which made it possible to monitor the location of the composition.

### Example 3

The composition obtained features the following  
25 weight percentage ratio of the constituents thereof:

ethyl-alpha-cyanoacrylate 10

ethoxyethyl-alpha-cyanoacrylate 12

	polyvinylacetate having	
	a molecular mass of	
	15000	8
	dimethylsulphoxide	25
5	dimethylketone	21
	alpha-(3-amino-2,4,6-tri-iodo-	
	benzyl butyric acid	24

The composition is produced by the process described in Example 1. The polymerization time of the composition in the air at 25°C is 10 minutes, the polymerization rate of the composition on getting in contact with body tissues is 2.5 minutes.

The composition has been trialled clinically in male patient P., aged 46, operated upon for cancer of the pancreatic head. Radical pancreatoduodenectomy according to Whipple was performed, involving occlusion of the pancreatic stump duct system by injecting the composition (3 ml) for occlusion of ducts and cavities of human body. It should be noted that surgery revealed microfocal fat necrosis in the region of the pancreatic tail. Postoperative coursing uneventful. Duration of postoperative hyperamylasemia - 5 days. No pancreatic juice discharge through the drains was observed in the postoperative period. The patient was dismissed in satisfactory state in 17 days after surgery.

#### Example 4

The composition obtained features the following

weight percentage ratio of the constituents thereof:

	ethyl-alpha-cyanoacrylate	15
	ethoxyethyl-alpha-cyanoacrylate	10
	polyvinylacetate having a mole-	
5	cular mass of 25000	11
	dimethylsulphoxide	18
	dimethylketone	20
	3-acetylaminomethyl-5-acetylamino-2,4,6-3-iodobenzoic acid	9
10	alpha-phenyl-beta-(3,5-diiodo-4-hydroxyphenyl) propionic acid	17

The composition is obtained according to the process described in Example 1. The polymerization time of the thus-obtained composition when exposed to the air at 25°C is 14 minutes. The rate of polymerization on getting in contact with body tissues is 1.5 minutes. The composition has been tested in a chronic experiment on a mongrel dog weighing 20 kg, according to the surgical procedure described in Example 1. Postmortem examination of the sacrificed animal carried out in 15 days after surgery revealed that the polymer plug filled the major pancreatic duct and the first- and second-order ducts in a solid layer. There was noted pronounced atrophy of the acinar pancreatic tissue, as well as proliferation of the fibrous tissue. The Langerhans' islets remained unaffected.

#### Example 5

The composition obtained features the following

weight percentage ratio of the constituents thereof:

	ethyl-alpha-cyanoacrylate	17
	ethoxyethyl-alpha-cyanoacrylate	17
	dimethylsulphoxide	19
5	dimethylketone	22
	alpha-phenyl-beta-(3,5-diiodo- -4-hydroxyphenyl) propionic acid	25

The composition is obtained according to the process described in Example 1. The polymerization time of the composition when exposed to the air at 25°C is 12 minutes, the polymerization time on getting in contact with body tissues is 2 minutes. The composition has been trialled clinically in male patient B, aged 38, suffering from a severe form of chronic painful pancreatitis. Once the patient had been subjected to endoscopic retrograde pancreatocnolangiography that revealed the catheter staying in the major pancreatic duct, he was given 5 ml of the proposed composition for a period of 50 seconds, with the ratio of its components as described hereinabove. The catheter was withdrawn from the pancreatic ducts just after the injection of the composition. No backward flowing of the composition was observed. The composition was injected under monitoring on an X-ray screen. The postoperative period uneventful. The control X-ray radiography carried out in ten days after surgery detected the polymer located in the major pancreatic duct. The patient was relieved of pain imme-

diately after surgery. The patient has not been complaining of pain within a year after surgery, he is not put on a diet, and has gained 5 kg in weight.

Example 6

5       The composition obtained features the following weight percentage ratio of the constituents thereof:

	ethyl-alpha-cyanoacrylate	12.5
	ethoxyethyl-alpha-cyanoacry-	
	late	12.5
10	dimethylsulphoxide	12
	dimethylketone	20
	3-acetylaminoethyl-5-acetylamino-	
	2,4,6-tri-iodobenzoic acid	43

15       The composition is obtained according to the process described in Example 1. The polymerization time of the composition when exposed to the air at 25°C is 10 minutes, the polymerization rate on getting in contact with body tissues is 3 minutes. The composition has been trialled clinically in a male  
20       patient, aged 28, suffering from a posttraumatic external pancreatic fistula through which the head and tail of the pancreas were free to drain. No communication of that pancreas portion with the duodenum occurred. Before surgery a total of 500 to 600 ml of  
25       the pancreatic juice was discharged through the fistula daily.

Occlusion of the fistular cavity and the pancreatic ducts of the pancreas head and tail was carried out

by injecting 12 ml of the proposed composition for a period of 30 seconds, whereupon the catheter was withdrawn from the fistular cavity. On X-ray radiography there was observed a complete filling of the duct system of the pancreas head and tail along with the fistular cavity. Once the catheter had been removed part of the composition flowed outwards. Postoperative coursing smooth and uneventful, no discharge of the pancreatic juice from the fistular cavity was observed. The patient was dismissed in a satisfactory state three days after surgery; was examined a year after surgery, no complaints. A scar is left at the site of the fistula. Glucose tolerance test revealed no diabetes mellitus. No radiopacity was revealed in the abdominal cavity on observation X-ray radiography.

#### Example 7

The composition obtained features the following weight percentage ratio of the constituents thereof:

	ethyl-alpha-cyanoacrylate	30
20	dimethylsulphoxide	15
	dimethylketone	21
	alpha-phenyl-beta-(3,5-diiodo- -4-hydroxyphenyl) propionic acid	34

The composition is obtained according to the process described in Example 1. The polymerization time of the composition when exposed to the air at 25°C is 14 minutes. The polymerization rate on getting

in contact with body tissues is 2 minutes. The composition has been tested in an experiment on a dog weighing 10 kg, according to the surgical procedure described in Example 1. The composition was injected into the pancreatic ducts in an amount of 1.2 ml. No complications were observed on the part of the pancreas within the postoperative period. The dog was sacrificed in 30 days after occlusion. The postmortem examination revealed pronounced atrophy of the pancreatic tissue. The polymer was found to locate in the major pancreatic duct in the form of individual conglomerates. On histologic examination the majority of the acini were replaced by connective tissue, some individual remaining acini were seen, embedded in the connective-tissue cords. The amount of the insular tissue was found to increase to a certain extent.

#### Example 8

The composition obtained features the following weight percentage ratio of the constituents thereof:

20	ethoxyethyl- $\alpha$ -cyanoacrylate	38
	dimethylsulphoxide	18
	dimethylketone	20
	$\alpha$ -phenyl- $\beta$ -(3,5-diiodo- -4-hydroxyphenyl) propionic acid	24

25 The composition is obtained according to the process described in Example 1. The polymerization time of the composition when exposed to the air at 25°C is 13 minutes. The polymerization rate on get-



ting in contact with body tissues is 1.5 minutes. The composition has been tested experimentally on a dog weighing 12 kg. The test animal was subjected to the supramedian laparotomy and duodenotomy. The major  
5 pancreatic duct was catheterized extraduodenally with a dia. 1 mm catheter. The aforementioned composition was injected along the catheter in an amount of 1.4 ml for 50 seconds. The accessory pancreatic duct was not ligated. The duodenal wound was stitched up with a  
10 single-row suture. The dog was put on a standard diet after surgery, and was sacrificed in 60 days after the surgical procedure. Postmortem findings: the pancreas is sharply reduced in size, no lobulation is observed. The polymer is found to locate in the major  
15 pancreatic duct in the form of individual conglomerates. Histologic examination: absence of the acinar cells, bad proliferation of the connective tissue, wherein the endocrinous cells are embedded as separate islets, the amount of which is somewhat increased.

20 For the sake of comparison given below are some exemplary composition formulations, wherein the constituents are selected to be out of the limits stated hereinabove.

#### Example 9

25 The composition obtained features the following weight percentage ratio of the constituents thereof:

ethyl-alpha-cyanoacrylate	15
ethoxyethyl-alpha-cyano-	

	acrylate	15
	dimethylsulphoxide	32
	dimethylketone	21
	alpha-(3-amino,2,4,6-tri-	
5	iodobenzyl) butyric acid	17

The composition is obtained according to the process described in Example 1. The polymerization time of the composition when exposed to the air at 25°C is 7 minutes. The polymerization time on getting  
10 in contact with body tissues is 1.1 minutes. The composition has been tested in an acute experiment on a mongrel dog weighing 12 kg. The surgical procedure of the experiment has been described above with reference to Example 1. Postmortem examination carried  
15 out one hour after surgery demonstrated the composition in the form of a dense polymer solid filling the major pancreatic duct, as well the first- and second-order ducts. The pancreas was somewhat indurated, no necrotic foci were detected. The composition has not  
20 been tested in a chronic experiment as not meeting the requirements imposed upon its characteristics.

#### Example 10

The composition obtained features the following weight percentage ratio of the constituents thereof:

25	ethyl-alpha-cyanoacrylate	10
	ethoxyethyl-alpha-cyano-	
	acrylate	12
	dimethylsulphoxide	20

dimethylketone	21
3-acetylaminomethyl-5-acetyl- amino-2,4,6-tri-iodobenzoic acid	37

The composition is obtained according to the  
5 process described in Example 1. The polymerization  
time of the composition when exposed to the air at 25°C  
is 15 minutes. The polymerization time on getting in  
contact with body tissues is 3 minutes. The composi-  
tion has been tested in a chronic experiment on a dog  
10 weighing 26 kg. The supramedian laparotomy was carri-  
ed out under intravenous hexenal anesthesia. Duode-  
notomy was followed by transduodenal catheterization  
of the major pancreatic duct, whereupon the aforesaid  
composition was injected along the catheter for 50 se-  
15 conds. Part of the composition flowed through the ac-  
cessory pancreatic duct into the duodenum. The duode-  
nal wound was stitched up. Postoperative coursing  
smooth and uneventful. The dog was sacrificed in 15 days  
after the occlusion. On postmortem examination the  
20 pancreas appeared much indurated, somewhat atrophied.  
The major pancreatic duct exhibited the fragments of the  
polymer plug in the form of individual conglomerates.  
Patency of the pancreatic duct system has restored.

#### Example 11

25 The composition obtained features the following  
weight percentage ratio of the constituents thereof:

ethyl-alpha-cyanoacrylate	13
ethoxyethyl-alpha-cyanoacry- late	13

	dimethylsulphoxide	8
	dimethylketone	20
	alpha-phenyl-beta-(3,5-diiodo-	
	-4-hydroxyphenyl) propionic	
5	acid	46

The composition is obtained according to the process described in Example 1. The polymerization time of the composition when exposed to the air at 25°C is 26 minutes. The polymerization time on getting in contact with body tissues is 8 minutes. The composition has not been tested in a chronic experiment as failing to meet the requirements imposed thereon.

#### Example 12

The composition obtained features the following weight percentage ratio of the constituents thereof:

	ethyl-alpha-cyanoacrylate	26
	ethoxyethyl-alpha-cyanoacrylate	26
	dimethylsulphoxide	16
	dimethylketone	24
20	3-acetylaminomethyl-5-acetylami-	
	no-2,4,6- tri-iodobenzoic acid	8

The composition is obtained according to the process described in Example 1. The thus-obtained composition is polymerizable when exposed to the air at 25°C within 14 minutes. The polymerization time of the composition on getting in contact with body tissues is 35 seconds. The composition has been tested in an acute experiment on a dog weighing 14 kg, the surgical

procedure being as described in Example 1. An observation X-ray radiographic examination of the abdominal viscera revealed no radiopacity in the pancreas projection. On postmortem examination of the animal in  
5 an hour after surgery numerous foci of hemorrhagic necrosis were observed, concerned with too early polymerization of the composition and with the resultant rupture of the interlobular ductules. The composition has not been tested in chronic experiments as  
10 not meeting the requirements imposed thereon.

CLAIMS:

1. A composition for occlusion of ducts and cavities of human body, characterized in that it incorporates alpha-cyanoacrylates, dimethylsulphoxide, dimethylketone and an iodine-containing radiopaque organic acid, or mixtures of such acids, the weight percentage ratio of the original constituents being as follows:

	alpha-cyanoacrylate	25 to 42
10	dimethylsulphoxide	12 to 25
	dimethylketone	20 to 24
	iodine-containing radiopaque organic acid, or mixtures of such acids	9 to 43

2. A composition as claimed in Claim 1, wherein the iodine-containing radiopaque organic acid in said composition are alpha-phenyl-beta-(3,5-diiodo-4-hydroxyphenyl) propionic acid, 3-acetylaminoethyl-5-acetylamino-2,4,6-tri-iodobenzoic acid, or alpha-(3-amino-2,4,6-tri-iodobenzyl) butyric acid.

3. A composition as claimed in Claims 1 or 2, which comprises additionally polyvinylacetate having a molecular mass of 15000 to 25000 in a proportion of 5 to 11 weight percent of the amount of alpha-cyanoacrylate.

4. A composition for occlusion of ducts and cavities of human body as claimed in any of Claims 1 to 3, substantially as disclosed in the description or in any of Examples 1 to 8.